{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T01:14:04Z","timestamp":1748049244703},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T00:00:00Z","timestamp":1439856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T00:00:00Z","timestamp":1439856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1038\/leu.2015.201","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T08:41:40Z","timestamp":1439887300000},"page":"2117-2117","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Should we also evaluate SET together with CIP2A for the treatment with second-generation tyrosine kinase inhibitors in chronic myeloid leukemia?"],"prefix":"10.1038","volume":"29","author":[{"given":"I","family":"Crist\u00f3bal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Manso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Gonz\u00e1lez-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Garc\u00eda-Foncillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,18]]},"reference":[{"key":"BFleu2015201_CR1","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/leu.2015.71","volume":"29","author":"CM Lucas","year":"2015","unstructured":"Lucas CM, Harris RJ, Holcroft AK, Scott LJ, Carmell N, McDonald E et al. Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients. Leukemia 2015; 29: 1514\u20131523.","journal-title":"Leukemia"},{"key":"BFleu2015201_CR2","doi-asserted-by":"publisher","first-page":"9157","DOI":"10.1073\/pnas.1317630111","volume":"111","author":"M Janghorban","year":"2014","unstructured":"Janghorban M, Farrell AS, Allen-Petersen BL, Pelz C, Daniel CJ, Oddo J et al. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc Natl Acad Sci USA 2014; 111: 9157\u20139162.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2015201_CR3","doi-asserted-by":"publisher","first-page":"6660","DOI":"10.1182\/blood-2010-08-304477","volume":"117","author":"CM Lucas","year":"2011","unstructured":"Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE . Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 2011; 117: 6660\u20136668.","journal-title":"Blood"},{"key":"BFleu2015201_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","volume":"8","author":"P Neviani","year":"2005","unstructured":"Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein. Cancer Cell 2005; 8: 355\u2013368.","journal-title":"Cancer Cell"},{"key":"BFleu2015201_CR5","doi-asserted-by":"crossref","first-page":"12128","DOI":"10.18632\/oncotarget.3665","volume":"6","author":"S Wang","year":"2015","unstructured":"Wang S, Xie W, Wang D, Peng Z, Zheng Y, Liu N et al. Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia. Oncotarget 2015; 6: 12128\u201312140.","journal-title":"Oncotarget"},{"key":"BFleu2015201_CR6","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1172\/JCI31095","volume":"117","author":"P Neviani","year":"2007","unstructured":"Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007; 117: 2408\u20132421.","journal-title":"J Clin Invest"},{"key":"BFleu2015201_CR7","doi-asserted-by":"publisher","first-page":"5941","DOI":"10.1182\/blood-2010-08-300772","volume":"117","author":"A Salas","year":"2011","unstructured":"Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, Saddoughi SA et al. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2\u2009A. Blood 2011; 117: 5941\u20135952.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2015201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015201","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015201.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:26:59Z","timestamp":1648744019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,18]]},"references-count":7,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["BFleu2015201"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.201","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,18]]},"assertion":[{"value":"18 August 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}